Biochemical Engineering


Professor Eli Keshavarz-Moore

Professor of Bioprocess Science & Enterprise

Chair, UG Exam Board, Vice-Dean (International) and Careers Liaison Officer

  • Professor Eli Keshavarz Moore

    Reader, Department of Biochemical Engineering, UCL (2006-present)

  • Senior Lecturer, Department of Biochemical Engineering, UCL (1998-2006)
  • Lecturer, Biochemical Engineering, UCL (1990-1998)
  • Honorary Lecturer, Department of Chemical and Biochemical Engineering,UCL (1988-1990)
  • Consultant, Coopers & Lybrand Associates Limited, U.K. (1979-1983)
  • Analyst, ICL Dataskil , U.K. (1978-1979)
  • Corporate Member, Institution of Chemical Engineers
  • Member, judging panel. SET for Britain and Europe award (2005-present)

Prof Eli Keshavarz-Moore



Roberts Building, 313
Torrington Place


  • Professor of Bioprocess Science & Enterprise
    Dept of Biochemical Engineering
    Faculty of Engineering Science

Joined UCL


The central theme of Eli’s research has been to investigate the interaction between cell engineering and fermentation and downstream processing. The early focus was on the impact of recombinant technology on the processing of macromolecules; in particular proteins with specific attention to the way fermentation strategy may control the location of the protein, and its titre in order to adapt the best harvesting strategy and enable the provision of generic process options for downstream separation. The range of organisms studied included both microbial and fungal systems. This extended into processing of recombinant macromolecules specifically antibodies to transgenic plants as an alternative route to production. The largest challenge is in the early stages where the material for processing is to be prepared and then separated. The work has complemented the mainstream microbial and animal cell studies. Her research has been the basis for further study on creating a framework for rapid choice of a whole bioprocess prior to detailed design. As a one of the 5 principal investigators of IMRC for bioprocessing (2007-2012), she brought a new theme based on the specific, knowledge-based design of cells and their propagation in bioreactors in response to the needs and demands of downstream/ purification stages. This is a novel approach to the whole process design. Hitherto, downstream operations have had to deal with every increasing higher concentrations of biomass and titres of products, and the removal of challenging contaminants arising from early stage processing, whilst operating within the constraints set by regulatory authorities. The new approach has aimed at easing this burden. In further research grants, the challenge of harnessing complex, large plasmids and phages which are potential candidates for a new generation of biopharmaceuticals such as multivalent vaccines and debilitating conditions such as muscular dystrophy has been considered. Their characteristics such as size are setting new barriers both at the synthesis and separation stages due to the likelihood of very low titres, a high level of genomic contamination and high potential degradation. Currently, her collaboration with leading centres in the UK and Europe (Warwick, Kent, Oulu, Zurich) is helping scientists from these centres to re-engineer host cell organisms so they can be used to enhance or create alternative routes for bioprocess sequences.
Award year Qualification Institution
1988 PhD
Doctor of Philosophy
Biochemical Engineering
University College London
1985 MEng
Master of Engineering
Biochemical Engineering
University of Melbourne
1977 DIC
Diploma of the Imperial College
Biochemical Engineering
Imperial College of Science, Technology and Medicine
1977 MSc (Hons)
Master of Science (Honours)
Management studies
Imperial College of Science, Technology and Medicine
1976 BEng hons
Bachelor of Engineering (Honours)
Chemical Engineering
Imperial College of Science, Technology and Medicine

Teaching and Training Activities

Since 2000, Eli Keshavarz-Moore has led the development and implementation of innovative enterprise training at the bioprocessing/life sciences interface. The training program encompasses a range of courses at undergraduate and postgraduate levels and has extended to include business enterprise for industry in the healthcare and biotechnology sectors. As a result, over 600 students have been trained from across UCL, including the Faculties of Engineering Sciences, Life Sciences and Medicine together with a mix of post-experience delegates from other institutions including the London Business School.